Approximately 390 million dengue virus infections occur every year, out of which 96 million of the cases manifest clinically. It is estimated that 3.9 billion individuals are at risk of getting a dengue virus infection, with Asia reported to represent nearly 70% of the global disease burden. The dengue pipeline analysis explores the latest medications and vaccinations, currently in development. The surge in dengue cases, along with rapid advancements in vaccine development and regulatory support, is likely to expedite the development of several promising dengue drugs in the coming years.
Report Coverage
The Dengue Pipeline Analysis Report by the publisher gives comprehensive insights into dengue therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Dengue. The dengue report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The dengue pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with dengue treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to dengue.
There is no specific treatment for dengue, but there are some common dengue therapeutics that can aid in managing symptoms. Pain relievers such as Acetaminophen (Tylenol) are widely used for fever and muscle pain. Pharmaceutical companies are actively developing novel drug candidates such as antiviral agents, vaccines, and monoclonal antibodies. Additionally, streamlined approval processes and incentives for new dengue drugs, along with dengue treatment guidelines, are poised to improve patient outcomes and support pipeline expansion in the coming years. In May 2024, the World Health Organization (WHO) prequalified TAK-003, a dengue vaccine developed by Takeda. TAK-003 is a live-attenuated vaccine containing weakened versions of all four dengue virus serotypes. It is recommended for children aged 6-16 years in high-burden areas. WHO prequalification enables procurement by agencies like UNICEF and PAHO, expanding global vaccine access.
The incidence of dengue is reported to be dramatically increasing worldwide in recent decades. In 2023, the highest number of dengue cases was recorded, with more than 6.5 million people affected and over 7300 dengue-related deaths.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials, with a substantial number of dengue emerging drugs undergoing clinical development. Phase II holds the largest share at 50%, demonstrating strong advancements in Dengue drug development. Phase III follows with 41%, highlighting promising late-stage trials. Phase I contributes 5%, while Early Phase I accounts for 4%, indicating continuous innovation. These developments enhance treatment options, drive market growth, and improve global efforts to combat Dengue effectively.
Dengue Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the dengue pipeline analysis include oligonucleotide, peptide, and small molecule. The dengue report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for the disease. The pipeline includes antiviral and vaccine-based approaches to combat the disease. As per a press release by Panacea Biotec, the company’s tetravalent dengue vaccine, DengiAll has entered Phase III trials in India. Additionally, antiviral candidates targeting dengue virus replication, such as EDP-938, are under investigation. These developments aim to address the growing burden of dengue globally.
Key Players in the Dengue Pipeline
The report for the dengue pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed dengue therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in dengue clinical trials:
Biological: Dengue Tetravalent Vaccine (TDV)
Sponsored by Takeda, the objective of this randomized, double-blinded, multicenter clinical trial is to investigate the immunogenicity and safety of Dengue Tetravalent Vaccine (TDV) for protection against dengue. The study is under Phase III clinical development and has an estimated 800 participants.
Key Questions Answered in the Dengue Pipeline Analysis Report
The Dengue Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for dengue. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within dengue pipeline insights.
This product will be delivered within 3-5 business days.
Report Coverage
The Dengue Pipeline Analysis Report by the publisher gives comprehensive insights into dengue therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Dengue. The dengue report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The dengue pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with dengue treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to dengue.
Dengue Pipeline Outlook
Dengue, a mosquito-borne disease, is caused by dengue virus and is spread by the bite of an infected Aedes mosquito. It is prevalent in tropical and subtropical areas and leads to flu-like symptoms such as high fever, skin rash and itching, headache, vomiting, and muscle and joint pain. Dengue fever can develop into severe dengue in a small number of cases._x000D__x000D_There is no specific treatment for dengue, but there are some common dengue therapeutics that can aid in managing symptoms. Pain relievers such as Acetaminophen (Tylenol) are widely used for fever and muscle pain. Pharmaceutical companies are actively developing novel drug candidates such as antiviral agents, vaccines, and monoclonal antibodies. Additionally, streamlined approval processes and incentives for new dengue drugs, along with dengue treatment guidelines, are poised to improve patient outcomes and support pipeline expansion in the coming years. In May 2024, the World Health Organization (WHO) prequalified TAK-003, a dengue vaccine developed by Takeda. TAK-003 is a live-attenuated vaccine containing weakened versions of all four dengue virus serotypes. It is recommended for children aged 6-16 years in high-burden areas. WHO prequalification enables procurement by agencies like UNICEF and PAHO, expanding global vaccine access.
Dengue Epidemiology
According to the World Health Organisation (WHO), around half of the global population is at risk of getting a dengue infection. It is estimated that 100 to 400 million dengue infections occur annually, with individuals having second-time infections at a greater risk of developing severe dengue.The incidence of dengue is reported to be dramatically increasing worldwide in recent decades. In 2023, the highest number of dengue cases was recorded, with more than 6.5 million people affected and over 7300 dengue-related deaths.
Dengue - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of dengue drug candidates based on several segmentations including:By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The pipeline assessment report covers 50+ drug analyses based on drug classes:
- Oligonucleotide
- Peptide
- Small Molecule
By Route of Administration
The dengue report assessment covers 50+ drug analyses based on the route of administration.- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials, with a substantial number of dengue emerging drugs undergoing clinical development. Phase II holds the largest share at 50%, demonstrating strong advancements in Dengue drug development. Phase III follows with 41%, highlighting promising late-stage trials. Phase I contributes 5%, while Early Phase I accounts for 4%, indicating continuous innovation. These developments enhance treatment options, drive market growth, and improve global efforts to combat Dengue effectively.
Dengue Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the dengue pipeline analysis include oligonucleotide, peptide, and small molecule. The dengue report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for the disease. The pipeline includes antiviral and vaccine-based approaches to combat the disease. As per a press release by Panacea Biotec, the company’s tetravalent dengue vaccine, DengiAll has entered Phase III trials in India. Additionally, antiviral candidates targeting dengue virus replication, such as EDP-938, are under investigation. These developments aim to address the growing burden of dengue globally.
Key Players in the Dengue Pipeline
The report for the dengue pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed dengue therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in dengue clinical trials:
- Novartis Pharmaceuticals
- Island Pharmaceuticals
- Takeda
- Sanofi Pasteur, a Sanofi Company
- PrimeVax Immuno-Oncology Inc.
Dengue Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for vitiligo. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of dengue drug candidates.Biological: Dengue Tetravalent Vaccine (TDV)
Sponsored by Takeda, the objective of this randomized, double-blinded, multicenter clinical trial is to investigate the immunogenicity and safety of Dengue Tetravalent Vaccine (TDV) for protection against dengue. The study is under Phase III clinical development and has an estimated 800 participants.
Drug: EYU688
Novartis Pharmaceuticals is conducting a Phase II clinical trial aimed at examining the efficacy, pharmacokinetics, and safety of dengue drug candidate EYU688, in comparison to placebo. The interventional study has enrolled about 5 subjects and is expected to be completed by February 2026.Key Questions Answered in the Dengue Pipeline Analysis Report
- Which companies/institutions are leading the dengue drug development?
- What is the efficacy and safety profile of dengue pipeline drugs?
- Which company is leading the dengue pipeline development activities?
- What is the current dengue commercial assessment?
- What are the opportunities and challenges present in the dengue pipeline landscape?
- What is the efficacy and safety profile of dengue pipeline drugs?
- Which company is conducting major trials for dengue drugs?
- Which companies/institutions are involved in dengue collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in dengue?
The Dengue Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for dengue. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within dengue pipeline insights.
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Dengue
4 Patient Profile: Dengue
5 Dengue: Epidemiology Snapshot
6 Dengue: Market Dynamics
7 Dengue: Key Facts Covered
8 Dengue, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Dengue Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Dengue Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Dengue Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Dengue Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Dengue, Key Drug Pipeline Companies
